RecruitingPhase 1NCT05218850
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
Butyrate Therapy in Hispanic Children With Ulcerative Colitis
Sponsor
Children's Hospital Los Angeles
Enrollment
10 participants
Start Date
Jun 29, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
Eligibility
Min Age: 7 YearsMax Age: 21 Years
Inclusion Criteria1
- years, mild to moderate ulcerative colitis
Exclusion Criteria2
- UC therapy within 4 weeks of study medication initiation
- infectious colitis, -pregnancy
Interventions
DRUGButyrate
Butyrate enemas will be administered once a day for 12 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05218850
Related Trials
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT0609512849 locations
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT060713121 location
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT0658132891 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744270 locations